Faeth Therapeutics, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Faeth announced positive Phase 2 topline results (as of October 30, 2026) for PIKTOR (serabelisib + sapanisertib) combined with paclitaxel in advanced endometrial cancer: 33% confirmed ORR (12 of 36 efficacy-evaluable patients) and 44% ORR in PIK3CA-mutant patients (7 of 16); median PFS 7.4 months with 62% 6-month PFS rate; safety profile acceptable with 12% hyperglycemia and 21% stomatitis (mostly low-grade). Company plans Phase 3 advancement pending regulatory alignment. Trial conducted with GOG Foundation across 42 treated patients with a median 2 prior therapy lines.
Why this rating
Clinical data validates lead asset and justifies Phase 3 progression; meaningful for $7.1M market-cap biotech dependent on single program success and future capital raises.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $18.10 ▲ 22.74% | at our read · unknown $14.74 | +10 min · unknown $12.02 ▼ 18.48% | +30 min · unknown $12.04 ▼ 18.31% | +1 hr · unknown $11.27 ▼ 23.57% | +4 hrs · unknown $12.29 ▼ 16.68% |
The stock had already moved -18.52% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.